Mitchell Psotka is a Cardiology physician. OpenAlex indexes 186 publications with 5,219 citations (h-index 35); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3300 Gallows Rd
Falls Church, VA 220423307
Telephone
703-776-7075Provider last certified this registry record 11 Mar 2022.
Clinical trials
- PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure at Inova
Sponsor: Inova Health Care Services
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- United Therapeutics CorporationProgram year20241 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20231 payment
- Merck Sharp & Dohme LLCProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
67.1%Aldosterone antagonist (MRA)20.5%Eplerenone51%Spironolactone49%Part D<11 patientsBeta blocker18.9%Metoprolol Succinate61%Carvedilol39%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
17.2%SGLT2 inhibitor17.2%Jardiance63%Farxiga38%Part D<11 patientsGenitourinary & hormones
6%Phosphodiesterase 5 Inhibitor6%Tadalafil100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Contemporary approach to cardiogenic shock care: a state-of-the-art review
Frontiers in Cardiovascular Medicine
2024 - Artificial Intelligence in Cardiovascular Clinical Trials
Journal of the American College of Cardiology
2024 - Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension
European Respiratory Journal
2024
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”